TIME FOR REIMBURSEMENT FOR ORPHAN DRUGS IN EU5

被引：0
|
作者：
Prada, M. [1 ]
Berard, I [2 ]
Walzer, S. [3 ]
Darba, J. [4 ]
Greenwood, B. [5 ]
机构：
[1] Intexo, Rome, Italy
[2] NEXTEP, Paris, France
[3] MArS Market Access & Pricing Strategy GmbH, Weil Am Rhein, Germany
[4] Univ Barcelona, Barcelona, Spain
[5] Decideum, London W8 7JB, England
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.04.1761
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY119
引用
收藏
页码：S264 / S264
页数：1
相关论文
共 50 条
  • [41] Reimbursement of orphan drugs: the Pompe and Fabry case in the Netherlands
    Rinke van den Brink
    Orphanet Journal of Rare Diseases, 9 (Suppl 1)
  • [42] Pricing and reimbursement of orphan drugs: the need for more transparency
    Simoens, Steven
    ORPHANET JOURNAL OF RARE DISEASES, 2011, 6
  • [43] Critical Assessment of Belgian Reimbursement Dossiers of Orphan Drugs
    Denis, Alain
    Mergaert, Lut
    Fostier, Christel
    Cleemput, Irina
    Hulstaert, Frank
    Simoens, Steven
    PHARMACOECONOMICS, 2011, 29 (10) : 883 - 893
  • [44] Critical Assessment of Belgian Reimbursement Dossiers of Orphan Drugs
    Alain Denis
    Lut Mergaert
    Christel Fostier
    Irina Cleemput
    Frank Hulstaert
    Steven Simoens
    PharmacoEconomics, 2011, 29 : 883 - 893
  • [45] Reimbursement of orphan drugs in Belgium: what (else) matters?
    Eline Picavet
    David Cassiman
    Steven Simoens
    Orphanet Journal of Rare Diseases, 9
  • [46] 北汽新能源EU5
    汽车观察, 2018, (11) : 194 - 194
  • [47] PRICING AND REIMBURSEMENT SYSTEM OF ORPHAN DRUGS IN THE CZECH REPUBLIC
    Prochazkova, M.
    Kubickova, P.
    Mazelova, J.
    Hambalek, J.
    Heislerova, M.
    VALUE IN HEALTH, 2013, 16 (07) : A474 - A474
  • [48] Reimbursement of orphan drugs in Belgium: what (else) matters?
    Picavet, Eline
    Cassiman, David
    Simoens, Steven
    ORPHANET JOURNAL OF RARE DISEASES, 2014, 9
  • [49] RECOMMENDATIONS AND REIMBURSEMENT STATUS OF ORPHAN DRUGS IN UE COUNTRIES
    Kawalec, P.
    VALUE IN HEALTH, 2015, 18 (07) : A678 - A678
  • [50] INSIGHTS INTO REIMBURSEMENT RATES AND TIMELINES FOR ORPHAN DRUGS IN IRELAND
    Marsh, S. E.
    VALUE IN HEALTH, 2019, 22 : S726 - S726
12345